187 related articles for article (PubMed ID: 32270628)
1. Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics.
Agrawal S; Heiss MS; Fenter RB; Abramova TV; Perera MA; Pacheco JA; Smith ME; Rasmussen-Torvik LJ; George AL
Clin Transl Sci; 2020 Sep; 13(5):941-949. PubMed ID: 32270628
[TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
5. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
6. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
7. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.
Panchenko E; Kropacheva E; Dobrovolsky A; Titaeva E; Zemlyanskaya O; Trofimov D; Galkina I; Lifshits G; Vereina N; Sinitsin S; Vorobyeva N; Grehova L; Zateyshchikov D; Zotova I; Vavilova T; Sirotkina O; Grontkovskaya A
Pharmacogenomics J; 2020 Oct; 20(5):687-694. PubMed ID: 32024944
[TBL] [Abstract][Full Text] [Related]
9. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
10. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
11. VKORC1 and CYP2C9 genotypic data-based dose prediction alone does not accurately predict warfarin dose requirements in some Malaysian patients.
Chua YA; Abdullah WZ; Yusof Z; Gan SH
Turk J Med Sci; 2015; 45(4):913-8. PubMed ID: 26422867
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
13. Effect of gene polymorphims on the warfarin treatment at initial stage.
Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
15. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
17. Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
Helin TA; Joutsi-Korhonen L; Asmundela H; Niemi M; Orpana A; Lassila R
Br J Clin Pharmacol; 2019 Aug; 85(8):1684-1691. PubMed ID: 30933373
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the impact of
Asari K; Takahashi H
Pharmacogenomics; 2020 Aug; 21(12):853-862. PubMed ID: 32700644
[No Abstract] [Full Text] [Related]
19. A multi-factorial analysis of response to warfarin in a UK prospective cohort.
Bourgeois S; Jorgensen A; Zhang EJ; Hanson A; Gillman MS; Bumpstead S; Toh CH; Williamson P; Daly AK; Kamali F; Deloukas P; Pirmohamed M
Genome Med; 2016 Jan; 8(1):2. PubMed ID: 26739746
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.
Wang F; Guo J; Zhang A
J Cardiovasc Pharmacol; 2019 Mar; 73(3):127-135. PubMed ID: 30688796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
